BR0300846A - Processo para produzir nanopartìculas de paclitaxel e albumina - Google Patents

Processo para produzir nanopartìculas de paclitaxel e albumina

Info

Publication number
BR0300846A
BR0300846A BR0300846-0A BR0300846A BR0300846A BR 0300846 A BR0300846 A BR 0300846A BR 0300846 A BR0300846 A BR 0300846A BR 0300846 A BR0300846 A BR 0300846A
Authority
BR
Brazil
Prior art keywords
albumin nanoparticles
paclitaxel
producing paclitaxel
albumin
producing
Prior art date
Application number
BR0300846-0A
Other languages
English (en)
Inventor
Simone Maschio
Maurizio Zenoni
Original Assignee
Acs Dobfar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acs Dobfar Spa filed Critical Acs Dobfar Spa
Publication of BR0300846A publication Critical patent/BR0300846A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)

Abstract

"PROCESSO PARA PRODUZIR NANOPARTìCULAS DE PACLITAXEL E ALBUMINA". A invenção refere-se a um processo para produzir nanopartículas de paclitaxel e albumina tendo propriedades antitumor, pelo qual uma mistura obtida adicionando-se paclitaxel na forma de pó em uma solução aquosa de albumina com clorofórmio é submetida ao tratamento de homogeneização de pressão elevada.
BR0300846-0A 2002-03-29 2003-03-26 Processo para produzir nanopartìculas de paclitaxel e albumina BR0300846A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002MI000681A ITMI20020681A1 (it) 2002-03-29 2002-03-29 Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina

Publications (1)

Publication Number Publication Date
BR0300846A true BR0300846A (pt) 2004-08-17

Family

ID=11449619

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0300846-0A BR0300846A (pt) 2002-03-29 2003-03-26 Processo para produzir nanopartìculas de paclitaxel e albumina

Country Status (15)

Country Link
US (2) US20030185894A1 (pt)
EP (1) EP1348431A1 (pt)
JP (2) JP4794115B2 (pt)
KR (1) KR20030078722A (pt)
CN (2) CN1259902C (pt)
AU (1) AU2003200920A1 (pt)
BR (1) BR0300846A (pt)
CA (1) CA2423915A1 (pt)
IL (1) IL154762A0 (pt)
IT (1) ITMI20020681A1 (pt)
MX (1) MXPA03002543A (pt)
NO (1) NO334407B1 (pt)
NZ (1) NZ524605A (pt)
RU (1) RU2003108821A (pt)
ZA (1) ZA200302040B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US20070117863A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
HU230338B1 (hu) * 1997-06-27 2016-02-29 Abraxis Bioscience Llc Gyógyászati hatóanyagokat tartalmazó új készítmények, eljárás ilyen készítmények előállítására és alkalmazására
AU2003299590B8 (en) 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
PL3248600T3 (pl) 2005-02-18 2020-09-07 Abraxis Bioscience, Llc Połączenia i sposoby podawania środków terapeutycznych i terapia skojarzona
CN101287507B (zh) * 2005-08-12 2012-12-05 刘江 用于淋巴靶向的方法和装置
BRPI0615265A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
JP5368093B2 (ja) 2005-08-31 2013-12-18 アブラクシス バイオサイエンス， エルエルシー 増大した安定性を有する難水溶性薬剤の組成物および調製の方法
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
EP1870649A1 (en) 2006-06-20 2007-12-26 Octapharma AG Lyophilisation targetting defined residual moisture by limited desorption energy levels
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
ES2460576T3 (es) * 2007-12-13 2014-05-13 Novartis Ag Procedimiento para preparar una sustancia farmacológica en partículas y cristalina
WO2009126401A1 (en) * 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
EP2156823A1 (en) * 2008-08-14 2010-02-24 Pharmatex Italia Srl Process for the preparation of sterile powdered pharmeceutical compounds in the form of micro and nanoparticles
CN101658516B (zh) * 2008-08-26 2011-10-05 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
HUE047376T2 (hu) 2009-04-15 2020-04-28 Abraxis Bioscience Llc Prionmentes nanorészecske-készítmények és elõállításuk
WO2011017835A1 (en) * 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
CA2785926A1 (en) * 2009-12-31 2011-07-07 Mannkind Corporation Injectable formulations for parenteral administration
LT2552438T (lt) 2010-03-26 2016-09-26 Abraxis Bioscience, Llc Hepatoceliulinės karcinomos gydymo būdai
NZ628423A (en) 2010-03-29 2016-03-31 Abraxis Bioscience Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
KR100971087B1 (ko) * 2010-05-06 2010-07-16 김현수 불투명부에 암막기능을 갖는 블라인드지의 제직방법
SG186112A1 (en) 2010-06-04 2013-01-30 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
CN102274190B (zh) * 2010-06-11 2012-12-05 上海现代药物制剂工程研究中心有限公司 一种注射用紫杉醇白蛋白亚微粒及其制备方法
CN102078306A (zh) * 2011-01-11 2011-06-01 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂
RU2705998C2 (ru) 2011-12-14 2019-11-13 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Применение полимерных эксципиентов для лиофилизации или заморозки частиц
RU2014141615A (ru) 2012-03-16 2016-05-10 Тайхо Фармасьютикал Ко., Лтд. Новое противоопухолевое средство, включающее комбинацию трех агентов
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP2968254B1 (en) 2013-03-12 2020-04-22 Abraxis BioScience, LLC Methods of treating lung cancer
KR20150127187A (ko) 2013-03-14 2015-11-16 아브락시스 바이오사이언스, 엘엘씨 방광암의 치료 방법
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
AU2016285720C1 (en) 2015-06-29 2022-02-03 Abraxis Bioscience, Llc Methods of treating epithelioid cell tumors
CN105012251A (zh) * 2015-08-24 2015-11-04 吉林大学 注射用紫杉烷类药物白蛋白纳米粒冻干制剂及制备方法
CN109890422A (zh) * 2016-09-06 2019-06-14 梅约医学教育与研究基金会 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法
EP3520824A4 (en) 2016-09-27 2020-04-29 Sogang University Research Foundation COMPOSITION FOR THE HEPATIC ARTERIAL CHEMOEMBOLISATION USING HUMAN SERUM ALUMINUM NANOPARTICLES WITH AN ANTI-DRIVING AGENT AND METHOD FOR THE PRODUCTION THEREOF
US11419842B2 (en) * 2016-10-27 2022-08-23 Zhuhai Beihai Biotech Co., Ltd. Neutral pH compositions of Docetaxel and human serum albumin
SG11202009145PA (en) 2018-03-20 2020-10-29 Abraxis Bioscience Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
CN108524452A (zh) * 2018-05-08 2018-09-14 辽宁大学 一种紫杉醇白蛋白纳米粒的制备方法和应用
CN110496111B (zh) * 2018-05-18 2021-07-23 国家纳米科学中心 一种白蛋白纳米复合结构及其制备方法和应用
MX2022004989A (es) 2019-10-28 2022-07-21 Abraxis Bioscience Llc Composiciones farmaceuticas de albumina y rapamicina.
CN110585444A (zh) * 2019-10-31 2019-12-20 董军 一种中西医结合药物及其制备方法与应用
CN114681408B (zh) * 2020-12-26 2023-06-23 四川汇宇制药股份有限公司 白蛋白结合型紫杉醇纳米粒的制备方法
KR102526793B1 (ko) * 2021-11-03 2023-04-28 주식회사 에스엔바이오사이언스 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법
GB202401848D0 (en) 2024-02-11 2024-03-27 Univ College Dublin Nat Univ Ireland Dublin Albumin nanoparticles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9405798A (pt) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
DE69833487T9 (de) * 1997-06-12 2007-03-01 Innovata Plc, Ruddington Polymer-wirkstoff-konjugate zur behandlung von krebs
HU230338B1 (hu) * 1997-06-27 2016-02-29 Abraxis Bioscience Llc Gyógyászati hatóanyagokat tartalmazó új készítmények, eljárás ilyen készítmények előállítására és alkalmazására
EP1100494A1 (en) * 1998-07-30 2001-05-23 Novopharm Biotech, Inc. Pharmaceutically composition comprising an aqueous solution of paclitaxel and albumin
US20020041898A1 (en) * 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
CA2406484A1 (en) * 2000-04-10 2001-10-18 Moshe Flashner-Barak Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Also Published As

Publication number Publication date
CN1911446A (zh) 2007-02-14
ITMI20020681A0 (it) 2002-03-29
US20030185894A1 (en) 2003-10-02
NO20031448L (no) 2003-09-30
JP2003300878A (ja) 2003-10-21
EP1348431A1 (en) 2003-10-01
CA2423915A1 (en) 2003-09-29
CN1448128A (zh) 2003-10-15
IL154762A0 (en) 2003-10-31
ZA200302040B (en) 2003-09-17
RU2003108821A (ru) 2004-11-10
AU2003200920A1 (en) 2003-10-16
NO334407B1 (no) 2014-02-24
NZ524605A (en) 2004-03-26
JP4794115B2 (ja) 2011-10-19
ITMI20020681A1 (it) 2003-09-29
JP2011132253A (ja) 2011-07-07
CN1259902C (zh) 2006-06-21
US20060121119A1 (en) 2006-06-08
MXPA03002543A (es) 2005-08-26
KR20030078722A (ko) 2003-10-08
NO20031448D0 (no) 2003-03-28

Similar Documents

Publication Publication Date Title
BR0300846A (pt) Processo para produzir nanopartìculas de paclitaxel e albumina
BRPI0413318A (pt) forma de administração à prova de abuso termicamente formada sem extrusão e processo para a produção da mesma
BR0311663A (pt) Preparação em forma de pelìcula contendo uma substância ativa, uso de uma preparação e processo para a produção de uma preparação
MXPA04004452A (es) Uso de una mezcla de hialuronato de sodio y sulfato de condroitina para el tratamiento de osteartritis.
BRPI0407074A (pt) Método para produção de uma preparação revestida, preparação revestida, e, método para melhorar a dissolução do cloridreto de pioglitazona de uma preparação revestida com cloridreto de pioglitazona
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
BR0211028A (pt) Solução aquosa, método para formação de associações de fármaco e polìmero, composições farmacêuticas, método para formação de uma composição farmacêutica e produto
BR0304134A (pt) Métodos para produção de fluidos de tratamento e de fraturamento, para tratar e para fraturar uma formação subterrânea, e para realizar uma pluralidade de tratamentos de formação subterrânea, e, composição para um fluido de tratamento
BR0206164A (pt) Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
BR0305488A (pt) Método para produzir um substrato revestido e substrato revestido
BRPI0413967A (pt) polìmero solúvel em água, processo para preparar um polìmero solúvel em água, composição e solução aquosa
BRPI0416534A (pt) composições multiparticuladas com estabilidade melhorada
BRPI0411471A (pt) método para produzir um não-trançado fibroso e não-trançado fibroso
BR0316918A (pt) Encapsulato de co-acervato complexo, composição alimentìcia e processo para a preparação de um encapsulato de co-acervato complexo
BRPI0510129A (pt) corpo de cerámica, processo para produzir o mesmo e processo para produzir um pó de oxinitreto de alumìnio
BRPI0602671A (pt) processo para a preparação de terpolìmeros de nitrila de mooney baixa
BRPI0417672A (pt) processos para produzir composições de vìrus estáveis em armazenamento, composições de vìrus e imunogênicas
MY139498A (en) Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
BRPI0412676A (pt) agente redutor do teor de cromato solúvel em cimento e métodos para produção do mesmo
BR0318321A (pt) composição emulsificada e processo para produzir uma composição emulsificada
BRPI0417360A (pt) método para a preparação de multiparticulados farmacêuticos
BRPI0713371A2 (pt) método para a produção de um produto medicamentoso contendo olmesartan medoxomil, e, produto medicamentoso contendo olmesartan medoxomil
BR0109405A (pt) Processo para a produção de carrageninas, carrageninas, e, uso destas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: AMERICAN BIOSCIENCE, INC. (US)

Free format text: TRANSFERIDO DE: ACS DOBFAR S.P.A.

B25A Requested transfer of rights approved

Owner name: AMERICAN PHARMACEUTICAL PARTNERS, INC. (US)

Free format text: TRANSFERIDO POR FUSAO DE: AMERICAN BIOSCIENCE, INC.

B25D Requested change of name of applicant approved

Owner name: ABRAXIS BIOSCIENCE, INC. (US)

Free format text: ALTERADO DE: AMERICAN PHARMACEUTICAL PARTNERS, INC.

B25G Requested change of headquarter approved

Owner name: ABRAXIS BIOSCIENCE, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070139853/RJ DE 03/10/2007.

B25A Requested transfer of rights approved

Owner name: ABRAXIS BIOSCIENCE, LLC (US)

Free format text: TRANSFERIDO POR FUSAO DE: ABRAXIS BIOSCIENCE, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]